Background: To formulate individually tailored therapy for patients with early-stage breast cancer, it is necessary to identify biomarkers for predicting metastasis and survival. Methods: A homogeneous cohort of 92 T1-2N0M0 breast carcinoma patients with a long-term follow-up were divided into two groups: the metastasis group (n = 41) and the disease-free group (n = 51). We evaluated the ability of risk discrimination of six biomarkers, including S100A4, Met, bcl-2, p53, survivin, and HER-2/neu, in early-stage breast cancer. Results: In multiple logistic regression analysis, only S100A4 expression (odds ratio = 5.37, p = 0.008) and Met expression (odds ratio = 6.91, p = 0.002) were independent predictors of distant relapse. Multivariate Cox models showed S100A4 and Met expressions were associated with 10-year disease-free survival (DFS) (risk ratio 3.2 and 4.0, respectively); however, tumor size and histological grade were not significant predictors. The 10-year DFS of T1-2N0M0 patients was 55.4%. T1-2N0M0 patients with S100A4-positive tumors had a significantly worse 10-year DFS than those with S100A4-negative tumors (29.0 vs. 68.9 %, p = 0.001). The 10-year DFS in T1-2N0M0 patients with Met-negative tumors was 82.4 vs. 39.7% if Met expression was positive (p = 0.0002). S100A4, but not Met, was still a significant predictor of 10-year DFS in T1N0M0 breast carcinoma patients (p = 0.02). For the T2N0M0 subgroup, both S100A4 and Met were significantly correlated with survival. The 10-year DFS of T2N0M0 patients with S100A4-negative and Met-negative tumors was 92.3%; in those with S100A4-positive and Met-positive tumors, however, it was only 11.8%. Conclusions: S100A4 expression is an indicator of a poor prognosis for T1N0M0 breast cancer. In addition, the combination of S100A4 and Met expression gives the best risk group discrimination in the T2N0M0 subgroup. S100A4 expression appears to be an earlier step in the metastatic progression compared to Met expression in early-stage breast carcinoma.

Keywords:
S100A4, Met, Early-stage breast cancer
1.
Fisher B, Bauer M, Wickerham L, Redmond CK, Fisher ER: Relation of number of positive axillary lymph nodes to the prognosis of patients with primary breast cancer; an NSABP update. Cancer 1983;52:1551–1557.
2.
Clark GM, McGuire W: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988;15:20–25.
3.
McGuire W, Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756–1761.
4.
Mansour EG, Ravdin PM, Dressler L: Prognostic factors in early breast carcinoma. Cancer 1994;74:381–400.
5.
Schwirzke M, Schiemann S, Gnirke AU, Weidle UH: New genes potentially involved in breast cancer metastasis. Anticancer Res 1999;19:1801–1814.
6.
van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530–536.
7.
Ebralidze A, Tulchinsky E, Grigorian M, Afanasyeva A, Senin V, Revazova E, Lukanidin E: Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes Dev 1989;3:1086–1093.
8.
Davies BR, Davies MP, Gibbs FE, Barraclough R, Rudland PS: Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 1993;8:999–1008.
9.
Lloyd BH, Platt-Higgins A, Rudland PS, Barraclough R: Human S100A4 (p9Ka) induces the metastatic phenotype upon benign tumour cells. Oncogene 1998;30;17:465–473.
10.
Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R: Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 1996;17:1631–1637.
11.
Ambartsumian NS, Grigorian MS, Larsen IF, Karlstrom O, Sidenius N, Rygaard J, Georgiev G, Lukanidin E: Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 1996;13:1621–1630.
12.
Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR: Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 2000;15:1595–1603.
13.
Platt-Higgins AM, Renshaw CA, West CR, Winstanley JH, De Silva Rudland S, Barraclough R, Rudland PS: Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer. Int J Cancer 2000;89:198–208.
14.
Pedersen KB, Nesland JM, Fodstad O, Maelandsmo GM: Expression of S100A4, E-cadherin, alpha- and beta-catenin in breast cancer biopsies. Br J Cancer 2002;18:1281–1286.
15.
Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802–804.
16.
Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK, Comoglio PM: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene 1991;6:501–504.
17.
Komada M, Kitamura N: The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor. Oncogene 1993;8:2381–2390.
18.
Rosen EM, Nigam SK, Goldberg ID: Scatter factor and the c-met receptor: A paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994;127:1783–1787.
19.
Maulik G, Shrikhande A, Kijima T, Ma PC, Morrison PT, Salgia R: Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev 2002;13:41–59.
20.
Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, Matsuda M, Sakaguchi T, Hirao T, Nakano H: The prognostic significance of amplification and overexpression of c-met and c-erbB-2 in human gastric carcinomas. Cancer 1999;85:1894–1902.
21.
Wagatsuma S, Konno R, Sato S, Yajima A: Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 1998;82:520–530.
22.
Ghoussoub RA, Dillon DA, D’Aquila T, Rimm EB, Fearon ER, Rimm DL: Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 1998;82:1513–1520.
23.
Camp RL, Rimm EB, Rimm DL: Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 1999;86:2259–2265.
24.
Bedi A, Pasricha PJ, Akhtar AJ, Barber JP, Bedi GC, Giardiello FM, Zehnbauer BA, Hamilton SR, Jones RJ: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55:1811–1816.
25.
Nikiforov MA, Hagen K, Ossovskaya VS, Connor TM, Lowe SW, Deichman GI, Gudkov AV: p53 modulation of anchorage independent growth and experimental metastasis. Oncogene 1996;13:1709–1719.
26.
Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961–6965.
27.
Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799–1805.
28.
Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917–921.
29.
Sierra A, Castellsague X, Tortola S, Escobedo A, Lloveras B, Peinado MA, Moreno A, Fabra A: Apoptosis loss and bcl-2 expression: Key determinants of lymph node metastases in T1 breast cancer. Clin Cancer Res 1996;2:1887–1894.
30.
Silvestrini R, Daidone MG, Benini E, Faranda A, Tomasic G, Boracchi P, Salvadori B, Veronesi U: Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1,400 node-negative breast cancers. Clin Cancer Res 1996;2:2007–2013.
31.
Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N: Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127–134.
32.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
33.
Goldhirsch A, Wood WC, Senn HJ, Glick JH, Gelber RD: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995;87:1441–1445.
34.
Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G: The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Archiv 1994;424:47–51.
35.
Barbareschi M, Leonardi E, Mauri FA, Serio G, Palma PD: p53 and c-erb B-2 protein expression in breast carcinomas: An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 1992;98:408–418.
36.
Cheng SH, Tsou MH, Liu MC, Jian JJ, Cheng JC, Leu SY, Hsieh CY, Huang AT: Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000;63:213–223.
37.
Lee WY, Jin YT, Tzeng CC: Reciprocal expression of bcl-2 and p53 in breast ductal carcinoma. Anticancer Res 1996;16:3007–3012.
38.
Chu JS, Huang CS, Chang KJ: Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan. Cancer Letters 1998;131:145–152.
39.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkacauk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976–983.
40.
Kato T, Kimura T, Miyakawa R, Fujii A, Yamamoto K, Kameoka S, Nishikawa T, Kasajima T: Clinicopathologic study associated with long-term survival in Japanese patients with node-negative breast cancer. Br J Cancer 2000;82:404–411.
41.
Frkovic-Grazio S, Bracko M: Long-term prognostic value of Nottingham histological grade and its components in early (pT1N0M0) breast carcinoma. J Clin Pathol 2002;55:88–92.
42.
Yamauchi H, Stearns V, Hayes DF: When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001;19:2334–2356.
43.
Joensuu H, Isola J, Lundin M, Salminen T, Holli K, Kataja V, Pylkkanen L, Turpeenniemi-Hujanen T, von Smitten K, Lundin J: Amplification of erb B2 and erb B2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study. Clin Cancer Res 2003;9:923–930.
44.
Kolar Z, Murray PG, Zapletalova J: Expression of c-erb B-2 in node negative breast cancer does not correlate with estrogen reporter status, predictors of hormone responsiveness, or PCNA expression. Neoplasms 2002:49:110–113.
45.
Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, Camp RL, Rimm DL: Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 2003;97:1841–1848.
46.
Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K: c-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 2003;5:30–36.
47.
Volpi A, Nanni O. De Paola F, Granato AM, Mangia A, Monti F, Schittulli F, De Lena M, Scarpi E, Rosetti P, Monti M, Gianni L, Amadori D, Paradiso A: HER-2 expression and cell proliferation: Prognostic markers in patients with node-negative breast cancer. J Clin Oncol 2003;21:2708–2712.
48.
Kriajevska M, Cardenas MN, Grigorian MS, Ambartsumain NS, Georgiev GP, Lukanidin EM: Non-muscle myosin heavy chain as a possible target for protein encoded by metastasis-related mts-1 gene. J Biol Chem 1994;269:19679–19682.
49.
Grigorian MS, Tulchinsky EM, Zain S, Ebralidze AK, Kramerov DA, Kriajevska MV, Georgiev GP, Lukanidin EM: The mts-1 gene and control of tumour metastasis. Gene 1993;135:229–238.
50.
Keirsebilck A, Bonne S, Bruyneel E, Vermassen P, Lukanidin E, Mareel M, van Roy F: E cadherin and metastasin (mts-1/S100A4) expression levels are inversely regulated in two tumour cell families. Cancer Res 1998;58:4587–4591.
51.
Kimura K, Endo Y, Yonemura Y, Heizmann CW, Schafer BW, Watanabe Y, Sasaki T: Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 2000;16:1125–1131.
52.
Yonemura Y, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K, Kinoshita K, Ninomiya I, Sugiyama K, Heizmann CW, Schafer BW, Sasaki T: Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. Clin Cancer Res 2000;6:4234–4242.
53.
Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, Cohn M, Ambartsumian N, Christensen A, Selivanova G, Lukanidin E: Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: Functional consequences of their interaction. J Biol Chem 2001;276:22699–22708.
54.
Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao R, Cao Y, Lukanidin E: The metastasis-associated Mts1 (S100A4) protein could act as an angiogenic factor. Oncogene 2001;20:4685–4695.
55.
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999–2009.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.